 |
|
|
| |
Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
|
| |
| |
EASL 2023 June 23 Vienna
Heiner Wedemeyer1, Soo Aleman2, Maurizia Brunetto3,3,4,
Antje Blank5, Pietro Andreone6, Pavel Bogomolov7,
Vladimir Chulanov8, Nina Mamonova8, Natalia Geyvandova8, Morozov Viacheslav9, Olga Sagalova10, Tatyana Stepanova11, Dmitry Manuilov12, Renee-Claude Mercier12,Qi An12,
John F. Flaherty12, Anu Osinusi12, Audrey Lau12,
Julian Schulze zur Wiesch13, Markus Cornberg14, Stefan Zeuzem15,16, Pietro Lampertico17,18.
|
| |
|
|
|
|
|
